| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.07 | 0.02 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.02 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.085 | 0.03 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.03 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.065 | 0.03 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.03 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.069 | 0.03 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.03 |